Pfenex Inc. - Investors Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis Submitted as a 505(b)(2) NDA with an Expected Ten-Month Review Mon, 10 Dec 2018 08:05:00 -0500 Pfenex Reports Third Quarter Results and Provides Business Update On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018 Wed, 07 Nov 2018 16:05:00 -0500 Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7 Thu, 25 Oct 2018 16:05:00 -0400 Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules Mon, 01 Oct 2018 16:10:00 -0400 Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference Fri, 21 Sep 2018 17:03:00 -0400